$1.52 Million is the total value of Cormorant Asset Management, LP's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ERASCA INC | $32,548 | -30.2% | 10,813,246 | 0.0% | 2.14% | -31.3% | ||
| DSGN | DESIGN THERAPEUTICS INC | $29,716 | -43.8% | 5,150,000 | 0.0% | 1.96% | -44.7% | |
| RAIN | RAIN ONCOLOGY INC | $26,033 | +9.2% | 2,978,660 | 0.0% | 1.71% | +7.5% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $22,542 | +2.4% | 2,893,717 | 0.0% | 1.48% | +0.7% | |
| VECT | VECTIVBIO HLDG AG | $21,587 | -1.8% | 2,536,617 | 0.0% | 1.42% | -3.3% | |
| EWTX | EDGEWISE THERAPEUTICS INC | $19,656 | -25.4% | 2,946,887 | 0.0% | 1.29% | -26.6% | |
| AXNX | AXONICS INC | $17,581 | -12.7% | 322,240 | 0.0% | 1.16% | -14.1% | |
| TANGO THERAPEUTICS INC | $16,262 | -45.5% | 4,116,949 | 0.0% | 1.07% | -46.4% | ||
| RCKT | ROCKET PHARMACEUTICALS INC | $14,878 | -12.5% | 868,550 | 0.0% | 0.98% | -13.8% | |
| CYTK | CYTOKINETICS INC | $10,416 | -23.2% | 296,000 | 0.0% | 0.69% | -24.4% | |
| STOK | STOKE THERAPEUTICS INC | $9,061 | -9.8% | 1,087,807 | 0.0% | 0.60% | -11.2% | |
| PRIME MEDICINE INC | $9,033 | -33.8% | 734,350 | 0.0% | 0.60% | -34.8% | ||
| PHVS | PHARVARIS N V | $6,577 | -28.4% | 816,460 | 0.0% | 0.43% | -29.6% | |
| VIGIL NEUROSCIENCE INC | $6,038 | -21.7% | 616,786 | 0.0% | 0.40% | -22.9% | ||
| AVIR | ATEA PHARMACEUTICALS INC | $5,183 | -30.4% | 1,547,181 | 0.0% | 0.34% | -31.5% | |
| VERV | VERVE THERAPEUTICS INC | $5,047 | -25.5% | 350,000 | 0.0% | 0.33% | -26.7% | |
| IDYA | IDEAYA BIOSCIENCES INC | $4,806 | -24.4% | 350,000 | 0.0% | 0.32% | -25.6% | |
| GHRS | GH RESEARCH PLCordinary shares | $4,738 | -17.8% | 593,043 | 0.0% | 0.31% | -19.2% | |
| GREENLIGHT BIOSCIENCS HLDS P | $3,973 | -63.4% | 9,188,659 | 0.0% | 0.26% | -63.9% | ||
| ICOSAVAX INC | $3,734 | -27.0% | 643,825 | 0.0% | 0.25% | -28.1% | ||
| ELEV | ELEVATION ONCOLOGY INC | $3,709 | +100.1% | 1,952,032 | 0.0% | 0.24% | +96.8% | |
| ELDN | ELEDON PHARMACEUTICALS INC | $2,874 | +3.5% | 1,217,882 | 0.0% | 0.19% | +1.6% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $2,767 | -59.9% | 612,079 | 0.0% | 0.18% | -60.6% | |
| CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,162 | +24.2% | 561,600 | 0.0% | 0.14% | +22.4% | |
| GLTO | GALECTO INC | $2,030 | +73.1% | 1,020,238 | 0.0% | 0.13% | +71.8% | |
| TALS | TALARIS THERAPEUTICS INC | $1,693 | +84.2% | 900,649 | 0.0% | 0.11% | +82.0% | |
| XFOR | X4 PHARMACEUTICALS INC | $1,417 | -12.4% | 1,628,980 | 0.0% | 0.09% | -13.9% | |
| BIOHAVEN LTD | $1,120 | -1.6% | 81,963 | 0.0% | 0.07% | -2.6% | ||
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $722 | -3.1% | 392,167 | 0.0% | 0.05% | -4.0% | |
| GRPH | GRAPHITE BIO INC | $489 | -26.1% | 199,547 | 0.0% | 0.03% | -27.3% | |
| CMMB | CHEMOMAB THERAPEUTICS LTDsponsored ads | $458 | -50.3% | 288,169 | 0.0% | 0.03% | -51.6% | |
| HARP | HARPOON THERAPEUTICS INC | $402 | +2.6% | 540,600 | 0.0% | 0.03% | 0.0% | |
| BCEL | ATRECA INC | $364 | +42.7% | 319,057 | 0.0% | 0.02% | +41.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.